Current Primary Outcome Measures •Numeric Rating Scale at 60 days and 90 days post procedure (lead removal) [ Time Frame: at 60 days (plus or minus 5 days) and 90 days (plus or minus 10 days) ] ...

Please provide your email address to receive an email when new articles are posted on . Patients used the device for 60 days, and effects persisted for 6 months. 71% of patients reported improved Neck ...

EDEN PRAIRIE, Minn., March 21, 2025 /PRNewswire/ — To follow up on the completion of its clinical proof-of-concept study, SynerFuse™ and its partner, Velentium Medical, today announced plans to scale ...

Pendergrast is an anesthesiology resident physician at the University of Michigan. The 1 in 5 Americans suffering from chronic pain may soon lose access to evidence-based interventions that have ...

The US Food and Drug Administration (FDA) has granted 510 (k) clearance for BlueWind Medical, Ltd.’s enhanced Revi® implantable tibial neuromodulator for treatment of urgency urinary incontinence (UUI ...

This independently analyzed real-world study conducted by research firm OM1 evaluated medical claims data in a comprehensive database of more than 340 million patient lives (OM1’s Real-World Data ...

A transcutaneous electrical stimulation system (TESS) is effective in reducing both symptoms and esophageal acid exposure time in patients with gastroesophageal reflux disease (GERD), according to a ...

TORONTO--(BUSINESS WIRE)--Epineuron is excited to announce Health Canada approval of its innovative nerve regeneration system, the PeriPulse™. Building on the success of its multi-center first ...

Please provide your email address to receive an email when new articles are posted on . Multiple Medicare Administrative Contractors have proposed to restrict coverage for peripheral nerve block ...